vs

Side-by-side financial comparison of BLUE RIDGE BANKSHARES, INC. (BRBS) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $20.8M, roughly 1.7× BLUE RIDGE BANKSHARES, INC.). BLUE RIDGE BANKSHARES, INC. runs the higher net margin — 20.4% vs -304.2%, a 324.6% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -5.2%). BLUE RIDGE BANKSHARES, INC. produced more free cash flow last quarter ($11.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -14.0%).

Blue Ridge Bankshares, Inc. is a U.S.-based financial holding company operating through its banking subsidiary. It offers retail and commercial banking services including deposit accounts, loans, and wealth management solutions, serving individual consumers and small to mid-sized businesses across Virginia and North Carolina.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BRBS vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.7× larger
RXRX
$35.5M
$20.8M
BRBS
Growing faster (revenue YoY)
RXRX
RXRX
+686.9% gap
RXRX
681.7%
-5.2%
BRBS
Higher net margin
BRBS
BRBS
324.6% more per $
BRBS
20.4%
-304.2%
RXRX
More free cash flow
BRBS
BRBS
$59.3M more FCF
BRBS
$11.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-14.0%
BRBS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BRBS
BRBS
RXRX
RXRX
Revenue
$20.8M
$35.5M
Net Profit
$4.2M
$-108.1M
Gross Margin
59.8%
Operating Margin
25.9%
-304.8%
Net Margin
20.4%
-304.2%
Revenue YoY
-5.2%
681.7%
Net Profit YoY
311.9%
39.6%
EPS (diluted)
$0.05
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BRBS
BRBS
RXRX
RXRX
Q4 25
$20.8M
$35.5M
Q3 25
$25.7M
$5.2M
Q2 25
$23.1M
$19.2M
Q1 25
$22.1M
$14.7M
Q4 24
$21.9M
$4.5M
Q3 24
$21.8M
$26.1M
Q2 24
$20.4M
$14.4M
Q1 24
$28.1M
$13.8M
Net Profit
BRBS
BRBS
RXRX
RXRX
Q4 25
$4.2M
$-108.1M
Q3 25
$5.6M
$-162.3M
Q2 25
$1.3M
$-171.9M
Q1 25
$-434.0K
$-202.5M
Q4 24
$-2.0M
$-178.9M
Q3 24
$946.0K
$-95.8M
Q2 24
$-11.4M
$-97.5M
Q1 24
$-2.9M
$-91.4M
Gross Margin
BRBS
BRBS
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BRBS
BRBS
RXRX
RXRX
Q4 25
25.9%
-304.8%
Q3 25
29.1%
-3327.6%
Q2 25
7.7%
-916.8%
Q1 25
-4.0%
-1297.9%
Q4 24
-14.1%
-4042.4%
Q3 24
7.1%
-377.1%
Q2 24
-59.2%
-697.4%
Q1 24
-11.7%
-698.4%
Net Margin
BRBS
BRBS
RXRX
RXRX
Q4 25
20.4%
-304.2%
Q3 25
21.8%
-3135.3%
Q2 25
5.6%
-894.2%
Q1 25
-2.0%
-1373.3%
Q4 24
-10.5%
-3935.5%
Q3 24
4.3%
-367.5%
Q2 24
-56.2%
-676.6%
Q1 24
-10.3%
-662.4%
EPS (diluted)
BRBS
BRBS
RXRX
RXRX
Q4 25
$0.05
$-0.17
Q3 25
$0.06
$-0.36
Q2 25
$0.01
$-0.41
Q1 25
$-0.01
$-0.50
Q4 24
$0.30
$-0.56
Q3 24
$0.01
$-0.34
Q2 24
$-0.47
$-0.40
Q1 24
$-0.15
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BRBS
BRBS
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$323.7M
$1.1B
Total Assets
$2.4B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BRBS
BRBS
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
BRBS
BRBS
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
BRBS
BRBS
RXRX
RXRX
Q4 25
$323.7M
$1.1B
Q3 25
$355.5M
$1.0B
Q2 25
$344.3M
$919.1M
Q1 25
$338.3M
$933.9M
Q4 24
$327.8M
$1.0B
Q3 24
$336.3M
$524.6M
Q2 24
$325.6M
$584.4M
Q1 24
$180.9M
$401.2M
Total Assets
BRBS
BRBS
RXRX
RXRX
Q4 25
$2.4B
$1.5B
Q3 25
$2.5B
$1.4B
Q2 25
$2.6B
$1.3B
Q1 25
$2.7B
$1.3B
Q4 24
$2.7B
$1.4B
Q3 24
$2.9B
$726.5M
Q2 24
$2.9B
$775.9M
Q1 24
$3.1B
$557.8M
Debt / Equity
BRBS
BRBS
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BRBS
BRBS
RXRX
RXRX
Operating Cash FlowLast quarter
$13.6M
$-46.1M
Free Cash FlowOCF − Capex
$11.9M
$-47.3M
FCF MarginFCF / Revenue
57.4%
-133.1%
Capex IntensityCapex / Revenue
8.1%
3.5%
Cash ConversionOCF / Net Profit
3.21×
TTM Free Cash FlowTrailing 4 quarters
$24.6M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BRBS
BRBS
RXRX
RXRX
Q4 25
$13.6M
$-46.1M
Q3 25
$6.4M
$-117.4M
Q2 25
$10.7M
$-76.4M
Q1 25
$-3.6M
$-132.0M
Q4 24
$-6.3M
$-115.4M
Q3 24
$24.1M
$-59.2M
Q2 24
$-4.8M
$-82.2M
Q1 24
$-7.5M
$-102.3M
Free Cash Flow
BRBS
BRBS
RXRX
RXRX
Q4 25
$11.9M
$-47.3M
Q3 25
$5.7M
$-117.6M
Q2 25
$10.5M
$-79.6M
Q1 25
$-3.6M
$-133.8M
Q4 24
$-6.9M
$-116.7M
Q3 24
$23.9M
$-63.8M
Q2 24
$-5.0M
$-83.4M
Q1 24
$-7.6M
$-109.0M
FCF Margin
BRBS
BRBS
RXRX
RXRX
Q4 25
57.4%
-133.1%
Q3 25
22.3%
-2272.5%
Q2 25
45.6%
-413.9%
Q1 25
-16.4%
-907.4%
Q4 24
-31.4%
-2567.7%
Q3 24
109.6%
-244.6%
Q2 24
-24.4%
-578.5%
Q1 24
-26.9%
-789.9%
Capex Intensity
BRBS
BRBS
RXRX
RXRX
Q4 25
8.1%
3.5%
Q3 25
2.7%
4.7%
Q2 25
0.6%
16.4%
Q1 25
0.1%
12.4%
Q4 24
2.7%
28.6%
Q3 24
1.1%
17.5%
Q2 24
0.8%
8.2%
Q1 24
0.2%
48.2%
Cash Conversion
BRBS
BRBS
RXRX
RXRX
Q4 25
3.21×
Q3 25
1.15×
Q2 25
8.22×
Q1 25
Q4 24
Q3 24
25.51×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons